VOSE vs. MOSE in EUS-FNB for Pancreatic Masses
Comparison of Specimen Quality Using Visual On-Site Evaluation Versus Macroscopic On-Site Evaluation in Endoscopic Ultrasound-Guided Fine Needle Biopsy of Solid Pancreatic Masses: A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Trial
The primary endpoint of this study was to evaluate whether the histopathological diagnostic accuracy of VOSE EUS-FNB using 22-gauge (22G) Franseen or 22G Trident (Trident™) needles is non-inferior to that of MOSE EUS-FNB in pancreatic solid masses. The secondary endpoints included diagnostic sensitivity, diagnostic specificity, median number of needle passes, puncture time, and cytological diagnostic accuracy.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200025
- Ruijin hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age above 18 years, male or female.
- Presence of a solid pancreatic mass detected by CT, MRI, PET-CT, or EUS, and scheduled for EUS-FNB for diagnostic purposes.
- Provision of signed written informed consent.
Exclusion Criteria:
- Contraindications to endoscopy, such as severe cardiovascular or cerebrovascular diseases.
- Coagulation disorders (International Normalized Ratio [INR] ≥ 1.5, platelet count ≤ 50 × 10^9/L) or current use of anticoagulant or antiplatelet medications.
- Confirmed or suspected pregnancy.
- Pathological diagnosis has already been established by other methods.
- Refusal to participate in the study, current participation in another clinical trial, or participation in another clinical trial within 60 days prior to enrollment.
- Any other conditions that preclude the performance of EUS-FNB.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: VOSE Group (Visual On-Site Evaluation)
Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and visible tissue cores are placed into formalin for visual grading. If no "red mixed specimen" is observed, additional passes are performed up to 3 passes. The number of passes and puncture time are recorded. |
VOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide. Visible tissue cores are placed into a formalin vial, gently shaken to dissolve blood, and visually graded with photographic recording. If the first-pass specimen is not a "red mixed specimen," additional passes are performed until a "red mixed specimen" appears or a maximum of 3 passes is reached. |
|
Aktiver Komparator: MOSE Group (Macroscopic On-Site Evaluation)
Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and the macroscopic visible core (MVC) length is measured. If the MVC is < 10mm, additional passes are performed until the total MVC is ≥ 10mm or up to 3 passes. The number of passes and puncture time are recorded. |
MOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide, and the length of the macroscopic visible core (MVC) is measured. If the total MVC length is less than 10 mm, additional passes are performed until the total MVC is ≥ 10 mm or a maximum of 3 passes is reached. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Histopathological diagnostic accuracy
Zeitfenster: Within 30 days after the EUS-FNB procedure
|
The diagnostic accuracy of histopathological tissue obtained by EUS-FNB in the VOSE group compared to the MOSE group, using the final surgical pathology or clinical/radiological follow-up as the gold standard. |
Within 30 days after the EUS-FNB procedure
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Diagnostic sensitivity
Zeitfenster: Within 30 days after the EUS-FNB procedure
|
The diagnostic sensitivity of VOSE and MOSE groups compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
|
Diagnostic specificity
Zeitfenster: Within 30 days after the EUS-FNB procedure
|
The diagnostic specificity of VOSE and MOSE groups compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
|
Median number of needle passes
Zeitfenster: During the EUS-FNB procedure
|
The number of needle passes required to obtain adequate tissue samples (until a "red mixed specimen" or MVC ≥ 10mm is observed, up to 3 passes). |
During the EUS-FNB procedure
|
|
Puncture time
Zeitfenster: During the EUS-FNB procedure
|
The duration of the puncture procedure (from the start of the first needle pass to the end of sampling). |
During the EUS-FNB procedure
|
|
Cytological diagnostic accuracy
Zeitfenster: Within 30 days after the EUS-FNB procedure
|
The diagnostic accuracy of liquid-based cytology obtained from residual specimens in VOSE and MOSE groups, compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- RJ2026164
- 82570763 (Andere Zuschuss-/Finanzierungsnummer: National Nature Science Foundation of China)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .